Enhancing Prognostic Precision: The Role of TMEM240 Methylation in Colorectal Cancer
Limitations of Current Testing Methods
Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths globally. Traditional blood-based markers like CEA and CA19-9 often lack the sensitivity and timeliness needed to detect early disease progression or treatment response. There is a clear unmet need for more accurate, responsive biomarkers to support clinical decision-making.
EG BioMed Presents TMEM240 Blood Test at AACR to Enhance Colorectal Cancer Prognostic Monitoring
Research Advances
EG BioMed is conducting long-term follow-up research in collaboration with the gastrointestinal cancer care teams at Taipei Medical University Hospital and Shuang Ho Hospital. EG BioMed identified TMEM240 hypermethylation as a robust blood-based marker using cfDNA from both Taiwanese and Western CRC patients. TMEM240 methylation was detectable in plasma 1–3 months before radiologic progression and significantly correlated with poor prognosis in advanced cases.
TMEM240 hypermethylation in plasma is a highly sensitive and specific biomarker for colorectal cancer. With 94.4% sensitivity and 97.7% accuracy, it enables earlier and more accurate detection of cancer progression—often 1–3 months before imaging or elevations in CEA and CA19-9. Compared to traditional markers, TMEM240 offers real-time insights into tumor dynamics, supporting personalized treatment decisions and improving clinical care.
Dr. Yao-Yu Hsieh, Director of the Department of Hematology and Oncology at Shuang Ho Hospital and a key research collaborator, presented this study at the AACR 2025 annual meeting.
Want to stay updated on EG BioMed’s latest technologies and research progress?
Follow us on LinkedIn、Facebook, and Instagram for real-time updates and insights!